These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [A woman with palmar and plantar hyperpigmentation]. van Tienhoven G; Wilmink JW Ned Tijdschr Geneeskd; 2011; 155(45):A4100. PubMed ID: 22085578 [TBL] [Abstract][Full Text] [Related]
4. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Lassere Y; Hoff P Eur J Oncol Nurs; 2004; 8 Suppl 1():S31-40. PubMed ID: 15341880 [TBL] [Abstract][Full Text] [Related]
5. [A case of severe hand-foot syndrome caused by capecitabine]. Shimomatsuya T; Mitsudou Y; Nakamura T; Yonezawa K; Shiraishi S; Fujino M; Maruhashi K Gan To Kagaku Ryoho; 2007 Jul; 34(7):1139-41. PubMed ID: 17637558 [TBL] [Abstract][Full Text] [Related]
6. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome? Do JE; Kim YC Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060 [TBL] [Abstract][Full Text] [Related]
7. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Saif MW; Elfiky A; Diasio R Clin Colorectal Cancer; 2006 Sep; 6(3):219-23. PubMed ID: 17026792 [TBL] [Abstract][Full Text] [Related]
8. Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding. Latif S; Fraga G; Gadzia J J Drugs Dermatol; 2010 Mar; 9(3):268-70. PubMed ID: 20232590 [TBL] [Abstract][Full Text] [Related]
9. Management of hand-foot syndrome induced by capecitabine. Gressett SM; Stanford BL; Hardwicke F J Oncol Pharm Pract; 2006 Sep; 12(3):131-41. PubMed ID: 17022868 [TBL] [Abstract][Full Text] [Related]
10. Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient. Tavares-Bello R J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1434-5. PubMed ID: 17958867 [No Abstract] [Full Text] [Related]
11. [Capecitabine-induced hyperpigmentation followed by hand-foot syndrome: a new case report]. Agharbi FZ; Meziane M; Benhemmne H; Daoudi K; Elmesbahi O; Mikou O; Mernissi FZ Ann Dermatol Venereol; 2012 Mar; 139(3):221-2. PubMed ID: 22401689 [No Abstract] [Full Text] [Related]
12. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. Narasimhan P; Narasimhan S; Hitti IF; Rachita M Cutis; 2004 Feb; 73(2):101-6. PubMed ID: 15027515 [TBL] [Abstract][Full Text] [Related]
13. Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report. Lee SD; Kim HJ; Hwang SJ; Kim YJ; Nam SH; Kim BS Korean J Intern Med; 2007 Jun; 22(2):109-12. PubMed ID: 17616027 [TBL] [Abstract][Full Text] [Related]
15. Onycholysis with the appearance of a "sunset" secondary to capecitabine. Maino KL; Norwood C; Stashower ME Cutis; 2003 Sep; 72(3):234-6. PubMed ID: 14533836 [TBL] [Abstract][Full Text] [Related]
16. Capecitabine and PPE syndrome: a case report. LoRusso PM Breast J; 2003; 9(1):64-5. PubMed ID: 12558679 [No Abstract] [Full Text] [Related]
17. [Progress of study on prevention and treatment of xeloda induced hand-foot syndrome by measures of Chinese and Western medicine]. Wang Y; Xu RR Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Feb; 27(2):182-4. PubMed ID: 17343012 [TBL] [Abstract][Full Text] [Related]
18. Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Disel U; Gürkut O; Abali H; Kaleağasi H; Mertsoylu H; Ozyilkan O; Saif MW Cutan Ocul Toxicol; 2010 Jun; 29(2):140-2. PubMed ID: 20298142 [TBL] [Abstract][Full Text] [Related]
19. Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine? Jeung HC; Chung HC Asia Pac J Clin Oncol; 2010 Sep; 6(3):141-3. PubMed ID: 20887492 [No Abstract] [Full Text] [Related]